Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

31
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
31
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

32
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
32
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

31
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
31

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emerging evidence of neutrophil extracellular traps in essential hypertension and target organ damage: pathophysiological insights and therapeutic implications.

Hypertension research : official journal of the Japanese Society of Hypertension·2026
Same author

Phototype-related Trichoscopic differences in lichen Planopilaris and frontal Fibrosing alopecia.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Central Systolic Blood Pressure and Left Ventricular Mass: Findings From the International 24-Hour Aortic Blood Pressure Consortium.

Journal of the American Heart Association·2026
Same author

Novel hypertension phenotypes based on cross-classification of 24-h brachial and aortic SBP.

Journal of hypertension·2026
Same author

KCNQ1 rs163184 Variant Modulates Susceptibility to Classic and DPP-4 Inhibitor-Associated Bullous Pemphigoid.

International journal of dermatology·2026
Same author

Intrathecal Nalbuphine Versus Other Opioids as Adjuvant to 0.5% Hyperbaric Bupivacaine in Caesarean Section: A Systematic Review and Meta-Analysis.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Sep 6, 2025

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

1.4K

Endothelial Dysfunction in Psoriasis: An Updated Review.

Panagiota Anyfanti1, Anastasia Margouta1, Kyriakos Goulas1

  • 1Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Frontiers in Medicine
|June 27, 2022
PubMed
Summary

Psoriasis patients face higher cardiovascular risks due to chronic inflammation, which drives endothelial dysfunction and atherosclerosis. Understanding these links can improve risk prediction and treatment for psoriasis patients.

Keywords:
atherosclerosiscardiovascular riskcirculating biomarkersendothelial dysfunctionpsoriasisvascular biomarkers

More Related Videos

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

488
Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test
06:35

Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test

Published on: April 27, 2016

17.7K

Related Experiment Videos

Last Updated: Sep 6, 2025

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

1.4K
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

488
Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test
06:35

Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test

Published on: April 27, 2016

17.7K

Area of Science:

  • Dermatology
  • Cardiology
  • Immunology

Background:

  • Psoriasis, a chronic inflammatory skin disease, is linked to increased cardiovascular morbidity and mortality.
  • Chronic inflammation in psoriasis contributes to endothelial dysfunction and accelerated atherosclerosis.
  • Endothelial dysfunction is an early marker for cardiovascular events.

Purpose of the Study:

  • To review the role of chronic inflammation and other mechanisms in psoriasis-related endothelial dysfunction.
  • To examine biomarkers of endothelial dysfunction in psoriasis.
  • To discuss the impact of psoriasis treatments on cardiovascular risk.

Main Methods:

  • Literature review of studies on psoriasis, inflammation, endothelial dysfunction, and cardiovascular risk.
  • Analysis of circulating and vascular biomarkers in psoriasis patients.
  • Evaluation of systemic treatment effects on endothelial function.

Main Results:

  • Chronic inflammation and endothelial dysfunction are key drivers of cardiovascular risk in psoriasis.
  • Various biomarkers indicate endothelial dysfunction in psoriasis patients.
  • Systemic treatments may impact endothelial function and cardiovascular risk.

Conclusions:

  • Understanding psoriasis-induced endothelial dysfunction is crucial for cardiovascular risk assessment.
  • Targeting inflammation and endothelial dysfunction may reduce cardiovascular burden in psoriasis.
  • Further research can refine risk prediction and therapeutic strategies.